GSK plc 6-K, filed May 4, 2022
GSK plc (GSK)
6-K
2022-05-04
For: 2022-05-04
View Original
Added on
July 04, 2026
About this 6-K
GSK plc filed this 6-K on May 4, 2022.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of 04 May 2022
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
Issued: 4 May 2022, London UK - LSE announcement
GSK announces Dr Vishal Sikka to join the Board as Non-Executive
Director
GlaxoSmithKline plc (LSE/NYSE: GSK) has today announced that Dr
Vishal Sikka, founder and CEO of Vianai Systems, will join the
Board of the Company as a Non-Executive Director. He will join the
Board with effect from the Haleon demerger.
Vishal has a distinguished background in technology and
particularly in the field of Artificial Intelligence (AI) and
Machine Learning, which is central to GSK's approach to R&D. He
is the founder and CEO of Vianai Systems, a Silicon Valley-based
company that provides advanced technological software and services
in AI and Machine Learning to large enterprises around the world.
Prior to founding Vianai Systems, Vishal served as CEO of Infosys
and as a member of the Executive Board of SAP SE. Vishal has a PhD
in Artificial Intelligence from Stanford University and has
co-authored several research abstracts related to AI, technology
and database management. He is also currently a Board member of
Oracle Corporation and BMW.
Commenting on the appointment, Sir Jonathan Symonds, Chair of
GSK said: "I am delighted
to welcome Vishal to GSK. He is an experienced board director and
an outstanding technologist who has been at the forefront of
advanced technologies such as AI and Machine Learning for decades.
Harnessing and applying these technologies to the discovery and
development of new medicines and vaccines is central to our R&D
approach, and Vishal's insight and expertise will be invaluable as
the company accelerates its efforts in this
area."
Vishal's appointment further strengthens the Board's expertise and
builds on other recent Non-Executive Director appointments,
including Dr Harry (Hal) C. Dietz, Professor of Genetic
Medicine at The Johns Hopkins University School of
Medicine; Charles
(Charlie) Bancroft, former Executive Vice President at Bristol
Myers Squibb (BMS), and Dr Anne Beal, former instructor in
paediatrics at Harvard Medical School and Massachusetts General
Hospital, and Chief Patient Officer at Sanofi.
A further non-executive appointment, with deep biopharma expertise,
is expected in July 2022.
Notes:
|
1.
|
The
appointment of Dr Vishal Sikka was made by the Board on the
recommendation of the Nominations & Corporate Governance
Committee. The Committee conducted an extensive search and
selection process for this appointment, using an external search
firm, which is a signatory of the Voluntary Code of Conduct for
Executive Search Firms. The external search firm provided a
diverse list of candidates who were approached, evaluated and
interviewed, against an agreed set of criteria aligned to the
Board's target skills matrix.
|
|
2.
|
The
Board has determined that Dr Sikka will be an independent
Non-Executive Director on appointment in accordance with the UK
Corporate Governance Code.
|
|
3.
|
Dr
Sikka will receive the standard basic fee for a Non-Executive
Director of £95,000 per annum.
(Dr
Sikka will be required to invest in GSK shares in accordance with
the Company's shareholder approved Non Executive remuneration
policy.)
|
|
4.
|
Membership
of other Committees will be announced in due course.
|
|
5.
|
Dr
Sikka does not have a service contract. He has a letter of
appointment which may be viewed by contacting the Company Secretary
at the Company's registered office.
|
|
6.
|
There
are no further disclosures to be made in respect of Dr Sikka's
appointment under Listing Rule 9.6.13R.
|
About GSK
GSK is a science-led global healthcare company. For further
information please visit www.gsk.com/about-us.
|
GSK enquiries:
|
|
|
|
|
Media
enquiries:
|
Tim
Foley
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Kathleen
Quinn
|
+1 202
603 5003
|
(Washington
DC)
|
|
|
|
|
|
|
Analyst/Investor
enquiries:
|
Nick
Stone
|
+44 (0)
7717 618834
|
(London)
|
|
|
Sonya
Ghobrial
|
+44 (0)
7392 784784
|
(Consumer)
|
|
|
James
Dodwell
|
+44 (0)
20 8047 2406
|
(London)
|
|
|
Mick
Readey
|
+44 (0)
7990 339653
|
(London)
|
|
|
Josh
Williams
|
+44 (0)
7385 415719
|
(London)
|
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
|
|
Frannie
DeFranco
|
+1 215
751 4855
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK
cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the Company's
Annual Report on Form 20-F for 2021, GSK's Q1 Results for 2022 and
any impacts of the COVID-19 pandemic.
Registered in England & Wales:
No.
3888792
Registered Office:
980
Great West Road
Brentford,
Middlesex
TW8
9GS
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: May
04, 2022
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|